This clinical trial focuses on advanced ovarian cancer or recurrent ovarian cancer, including cancers of the fallopian tubes and peritoneum. The study will test a new medication called Saruparib (also known as AZD5305), which comes in tablet form and is taken by mouth. The medicine will be studied both as a single treatment and in combination with other cancer medications.

The main goal of this research is to determine if Saruparib is safe to use and to understand how well it works in treating advanced ovarian cancer. The study will look at how patients’ bodies respond to the medication and what side effects may occur. During the study, patients will receive regular medical check-ups, including blood tests and imaging scans to monitor their health and how the cancer responds to treatment.

This is a master protocol study, which means it consists of several smaller studies testing different aspects of the treatment. Throughout the study, doctors will monitor various health indicators and collect information about how the medication affects the cancer. They will also measure the amount of medication in the blood and track changes in a substance called CA125, which can indicate how well the treatment is working.